Impact story - UCB Farchim SA January 2023 STI Leaders since PHARMACEUTICAL PRODUCTS
INTEGRATING GLOBAL AMBITION WITH LOCAL ACTION UCB’s Journey Towards Science-Based and Inclusive Sustainability. UCB Farchim SA, based in Bulle, Switzerland, is part of UCB, a global biopharmaceutical company headquartered in Belgium. Guided by the ambition to improve the lives of people with severe diseases, UCB places sustainability at the heart of its strategy. In Switzerland, this commitment translates into concrete actions to protect the planet, foster inclusion, and ensure long-term value creation for patients, employees, and society. Since joining the Swiss Triple Impact (STI) Programme in 2021, UCB Far- chim has reinforced its global “Health of the Planet” programme with measurable local commitments. These pledges complement the com- pany’s Science Based Targets initiative (SBTi) validation and its long-stan- ding work on a culture of inclusion.
39 - Swiss Triple Impact Programme - Impact Report 2025
© B Lab Switzerland | Access the table of contents
Made with FlippingBook - Share PDF online